Scrip
Clavis Pharma licenses improved gemcitabine candidate to Clovis Oncology
24 November 2009
Sukaina Virji
Please Login to read the full article.
24 November 2009
Sukaina Virji
Clavis Pharma of Norway has licensed its anticancer candidate CP-4126 to US-based Clovis Oncology in a deal worth up to $380 million, including $15 million up front.
CP-4126, the second programme in Clavis's pipeline, is a lipid-conjugated form of gemcitabine. An intravenous formulation is...
Please Login to read the full article.
RELATED CONTENT
COMMENT
Other Informa Comment
FEATURES
Other Informa Features
EVENTS
10 February 2010
London, UK
11 February 2010
London, UK
23 February 2010
London, UK
JOB OF THE WEEK
Promote your vacancy here
DIRECTORY
Scrip Directory 2009
